~~<i id='4EC4D7FFC5'><strike id='4EC4D7FFC5'><tt id='4EC4D7FFC5'><pre id='4EC4D7FFC5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：hotspot 2025-09-30 16:24:15 - browse：53149

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： 'Revelatory' study finds a smoking impact that remains after quitting

Wikipedia

focus

hotspot

focus

knowledge

focus

AdobeJustweeksafterNovoNordiskannouncedthatitsobesitydrugWegovycuttheriskofheartcomplicationsinamajo

WSS

Why did Pfizer dish out millions for a Super Bowl ad?

National associations that represent hospice owe an apology

Private equity deals in Medicare Advantage declines

Medical mystery: When a cough is not just a cough

Vaccine advisory panel ACIP left half staffed by HHS

For Medicare Advantage, Democrats want stronger protections around AI

entertainment

fashion

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

How digital tools helped lower hypertension in marginalized patients

Apple is now the first public company to be valued at $3 trillion

What we’ve learned from the Aduhelm mess

In age of alternative facts, a scholarly course on calling out crap

Wegovy improves function in certain heart failure patients

How one medical school became remarkably diverse

The dental labor crisis is a moment of opportunity

DIEP, the 'gold standard' of breast reconstruction, is under threat

What we’ve learned from the Aduhelm mess

focus

KalVista pill reduced swelling 'attacks' caused by genetic disease

Doctors' information doesn't help them choose wisely when sick

Intellia plays down concerns on accidental germline transmission

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Can U.S. cancer drug shortages be fixed?

hotspot

focus

knowledge

focus